The role of somatostatin analogues in complete antiandrogen treatment in patients with prostatic carcinoma

Journal of Experimental and Clinical Cancer Research

Volumn 16, Issue 1, 1997, Pages 119-126

  Vainas, G ^b   Pasaitou, V ^b   Galaktidou, G ^b   Maris, K ^b   Christodoulou, K ^b   Constantinidis, C ^b   Kortsaris, A H ^a  

^a THEAGENIO CANCER HOSPITAL   (Greece)

^b NONE

Author keywords

antiandrogen blockade; IGF 1 and EGF serum levels; prostate cancer; somatostatin analogues

Indexed keywords

ACID PHOSPHATASE PROSTATE ISOENZYME; ANTIANDROGEN; EPIDERMAL GROWTH FACTOR; FLUTAMIDE; OCTREOTIDE; PROSTATE SPECIFIC ANTIGEN; SOMATOMEDIN C; SOMATOSTATIN DERIVATIVE; TRIPTORELIN;

ADULT; AGED; ARTICLE; BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; HUMAN; INTRAMUSCULAR DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MALE; ORAL DRUG ADMINISTRATION; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE CARCINOMA; SUBCUTANEOUS DRUG ADMINISTRATION;

ACID PHOSPHATASE; AGED; AGED, 80 AND OVER; ANDROGEN ANTAGONISTS; ANTINEOPLASTIC AGENTS, HORMONAL; CARCINOMA; EPIDERMAL GROWTH FACTOR; HUMANS; INSULIN-LIKE GROWTH FACTOR I; MALE; MIDDLE AGED; OCTREOTIDE; PROSPECTIVE STUDIES; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; SOMATOSTATIN; SURVIVAL ANALYSIS;

EID: 0030932096     PISSN: 03929078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Huggins C.B., Stevens R.E. Jr and Hodges C.V. (1941): Studies on prostatic cancer II. The effects of castration on advanced carcinoma of the prostate gland Arch. Surg., 43: 209-233.
2. Santen R.J. (1990): Endocrine aspects of prostate cancer. In: Decker K.L. (ed.) Principles and Practice of Endocrinology and Metabolism, J.B. Lippincott Co, Philadelphia, pp 1658-63.
3. Vainas G.I. and Dimitriadis A.K. (1990): The hormone therapy of prostate cancer ed. by University Studio Press, Thessaloniki, Greece.
4. Meyer F.J. and Crawford E.D. (1994): The role of endocrine therapy in the management of local and distant recurrence of prostate cancer following radical prostatectomy or radiation therapy. The Urologic Clinics of N. America,Vol. 21, Nr 4, 707-715.
5. Labrie F., Dupont A., Belanger A., et al. (1982): New hormonal therapy in prostatic, carcinoma: Combined treatment with a LHRH-agonist and an antiandrogen J.Clin. Invest. Med., 5: 267-275.
6. Labrie F., Dupont A. and Belanger A. (1985): Complete androgen blockade for treatment of prostate cancer. In important Advances in oncology 1985,ed. by Lippincott Company, 193-217, Philadelphia, USA.
7. Crawford E.D., Elsenberger M.A., McLeod D.G., et al. (1990): A controlled trial of Leuprolide with and without flutamide in prostatic carcinoma. N. Engl. J. Med. 321: 419.
8. Serially A.V., Coy D.H. and Meyers C.A.: Hypothalamic regulatory hormones, Annu. Rev. Biochem.,47: 89-128, 1978.
9. Mascardo R.N. and Sherline P. Somatostatin ihibits rapid centrosomal separation and cell proliferation induced by epidermal growth facton. Endocrinology, 111: 1394-1396, 1982.
10. Reichlin D.: Somatostatin N. Engl. J. Med., 309: 1495-1501, 1556-1563, 1983.
11. Serially A.V. and Redding T.W.: Somatostatin analogs as adjuncts to agonists of luteinizing hormone-releasing hormone in the treatment of experimental prostate cancer. Proc. Natl Acad. Sci. USA, 84: 7275-7279, 1987.
12. Schally A.V. (1988): Oncological Applications of Somatostatin Analogues. Cancer Res., 48, 6977-6985.
13. Manni A., Boucher A., Demers L., et al. (1990): Inhibition of prolactin and growth hormone secretion in the treatment of breast and prostate cancer. Europ. J. Cancer, vol. 26, p. 162, abstr. N. 62.
14. Meyers F., Soares S. and deVere White R. (1991): A phase II study of Sandostatin in metastatic carcinoma of the prostate (CaP). Proc. Amer. Soc. Clin. Oncol., vol. 10, p. 176, abstr. N. 566.
15. Hierowski M.T., Liebow C., duSapin K., et al. (1985): Stimulation by Somatostatin of dephosphorylation of membrane proteins in pancreatic cancer MIA PaCa- 2 cell line. FEBS Lett., 179: 252-256.
16. Nilsson A., Isgaard J., Lindahl, et al. (1986): Regulation by growth hormone of numberof chondrocytes containing IGF-1 in ratgrowth plate. Wash. DC, 233: 571-574.